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ORIGINAL ARTICLE
Evaluation of Three Population-Based Strategies for
Fracture Prevention
Results of the Osteoporosis Population-Based Risk Assessment
(OPRA) Trial
Andrea Z. LaCroix, PhD,*† Diana S.M. Buist, PhD,* Susan K. Brenneman, PT, PhD,‡
and Thomas A. Abbott, III, PhD‡
Background: The integration of bone density testing into well-
designed fracture prevention programs that can be applied in pop-
ulations has not been studied.
Objectives: We sought to compare the outcomes of 3 strategies for
allocating bone density testing within an HMO-based fracture pre-
vention program.
Research Design: Women were randomly sampled and allocated to
one of 3 groups: (1) a universal group, in which all were offered
bone mineral density (BMD) testing (1986 contacted; 415 partici-
pated); 2) the SCORE group, in which women scoring  7 on the
SCORE questionnaire were invited for BMD testing (1940 con-
tacted; 576 participated); and (3) the Study of Osteoporotic Fracture
(SOF)-based group, in which women with  5 hip fracture risk
factors were invited for BMD testing (5342 contacted; 2176 partic-
ipated).
Subjects: Women aged 60–80 not taking hormone therapy or
osteoporosis medication were included.
Measures: Outcomes ascertained during 33 months of follow-up in
all women contacted included initiation of osteoporosis treatment
and hip and total fracture rates. Outcomes evaluated among all
participants included changes in fracture risk factors, osteoporosis
knowledge, and satisfaction with the program.
Results: Osteoporosis treatment rates did not differ among all
women contacted but were slightly higher among trial participants in
the universal and SCORE groups (21.1% and 20.2%, respectively;
versus 16.7% in the SOF-based group (P value versus universal 
0.04). Among all women contacted, fracture rates were lowest in the
universal group (74.11/1000) and differed significantly compared
with the SCORE (99.44/1000; P  0.009) and SOF-based groups
(91.77/1000;P  0.02). Knowledge about osteoporosis risk factors
was highest in the universal group and lowest in the SOF-based
group (P  0.01).
Conclusions: The degree to which BMD testing was offered to
women in a fracture prevention program significantly affected total
fracture rates, change in some fracture risk factors, and knowledge
about risk factors.
Key Words: bone density testing, fracture prevention,
osteoporosis screening programs
(Med Care 2005;43: 293–302)
In 1999, 291,000 hip fractures occurred among Americansaged 65 and older.1 Although reducing hip fracture rates
was an articulated goal of Healthy People 2000, rates have
failed to decline during the past decade.2 Not only are hip
fractures a significant cause of death, morbidity and disabil-
ity,3 but they cost an estimated $8.7 million in health care
annually.4 Clearly, effective, evidence-based, public health
strategies for reducing fracture risk in populations are needed.
Proponents of bone density testing argue that this mea-
surement is among the strongest predictors of future fracture,
it cannot be known from assessment of other fracture risk
factors, and is necessary for directing preventive and thera-
peutic measures to women with greatest fracture risk.5 Many
studies have shown that bone density testing results in higher
rates of osteoporosis treatment initiation.6–11 However, large
randomized trials have not been conducted to determine
whether bone density testing prevents hip and other osteopo-
rotic fractures. Moreover, the integration of bone density
testing into well-designed fracture prevention programs has
not been studied. The Osteoporosis Population-based Risk
Assessment (OPRA) Trial was designed to compare 3 strat-
egies for allocating bone density testing in a health mainte-
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nance organization, within the context of a fracture preven-
tion program that included risk factor assessment,
personalized feedback on risk factor reduction and education
about osteoporosis, and fracture prevention for all partici-
pants. Its purpose was to evaluate the impact of these strat-
egies on osteoporosis treatment, risk-related behaviors, os-
teoporosis knowledge and the occurrence of fractures to
provide evidence that might inform and improve the design of
fracture prevention programs in health care organizations.
METHODS
Study Setting and Population
The OPRA Trial was conducted at Group Health Co-
operative (GHC), a mixed-model health maintenance organi-
zation in western Washington State with more than 47,000
women enrollees aged 60 and older. Several elements of the
intervention program were modeled after Group Health Co-
operative’s Breast Cancer Screening program, an established
population-based program for breast cancer prevention that
incorporates risk factor assessment, personalized feedback
and risk-based mammography screening.12 The research pro-
tocol was reviewed and approved by the Human Subjects
Review Committee at GHC.
Intervention Trial Design, Recruitment, and
Follow-up
Participant Eligibility
Women aged 60–80 were eligible to participate if they
had not taken hormone replacement therapy or other osteo-
porosis medications for at least 12 months. Potentially eligi-
ble women were identified from GHC enrollment files on the
basis of age and computerized pharmacy information. From
this sampling frame, women were randomly assigned to 1 of
the 3 intervention groups as described below. The overall
recruitment target was to randomly select and allocate a
sufficient number of women to all 3 groups to yield approx-
imately 1000 bone density testing visits in our research clinic.
Universal Testing Group
In the universal testing group, bone mineral density
testing was offered to all women via written invitation.
Letters of invitation were sent to 1986 potentially eligible
women (Fig. 1). In all of the intervention groups, a second
letter of invitation was sent to women who did not respond to
the first letter. Of the 1986 women originally contacted, 1116
(56.2%) did not respond, 419 (21.1%) refused participation,
and 23 (1.2%) could not be contacted. A total of 428 women
(21.5%) agreed to participate and completed the bone density
FIGURE 1. Sampling strategies and which women had BMD screening and osteoporosis treatment referral for the 3 arms of the
OPRA randomized trial. 1All women in group A were eligible for BMD testing. Only women with a score of  7 on the SCORE
instrument were eligible for BMD testing in group B. Women with  5 risk factors from the SOF-based instrument were BMD
eligible in group C. 2The criterion for referring women to their personal physicians was identical for the 3 study groups. Women
with 5 fracture risk factors and low bone density (T-score of less than2.5 for women 60–64 years or a z-score less than0.43
for women  65 years) along with all women who reported a fracture after age 50 were referred for work-up and treatment of
possible osteoporosis. 3Women with a personal history of fracture who did not “risk-in” to BMD testing were referred for work-up
and treatment in accordance with the GHC osteoporosis guideline; all women with a personal history of fracture in the universal
and SCORE groups were offered BMD testing and referred as described above.
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testing clinic examination; of these, 13 were later found to be
ineligible because of osteoporosis medication use, leaving
415 participants in this group.
Simple Calculated Osteoporosis Risk Estimation
(SCORE) Testing Group
In the SCORE testing group, women were sent a letter
about the osteoporosis prevention program and asked to
complete the SCORE, a 6-item instrument developed by
Merck & Co (Appendix Fig. 1). Details about the develop-
ment and validation of the SCORE are published elsewhere.13
Briefly, the SCORE instrument was specifically developed to
identify women with bone density T-scores 2.0. Thus, the
instrument was calibrated to have 90% sensitivity for detect-
ing women with bone density T-scores less than this thresh-
old (approximately 70–80% of women in previous reports)
and also identified the 20–30% of women least likely to have
low bone density. A total of 1940 women were sent letters
describing the program and the SCORE questionnaire (Fig.
1). Of these, 1079 (55.6%) did not respond, 213 (11%)
refused participation, and 51 (2.6%) could not be contacted.
Completed SCORE questionnaires were received from 597
women (30.8%). Of these, 21 were found ineligible because
of osteoporosis medication use, resulting in a final sample
size of 576 participants in this group. A total of 425 women
(73.8% of those completing the SCORE questionnaire) had a
score of 7 or higher and were invited to the bone density
testing examination. A score of 7 or higher was used based on
recalibration in the original development cohort to achieve
sensitivity of 90% in women aged 60 and older.
Study of Osteoporotic Fracture (SOF)-Based
Testing Group
In the SOF-based intervention group, women were sent
a letter about the osteoporosis prevention program and asked
to complete a 17-item risk assessment adapted from known
predictors of hip fracture in the large SOF cohort (Appendix
Fig. 2).14 Women with 5 or more risk factors were invited by
telephone to the research clinic for bone mineral density
testing. In the original report from SOF, women aged 65 and
older with 5 or more risk factors (15% of the total cohort) and
bone mineral density in the lowest third of their age-specific
distribution (ie, z-score  0.43) experienced one-third of
all hip fractures in the population.14
Because the SOF strategy would result in a low per-
centage of women being offered bone density testing exam-
inations, more women were allocated to this group initially.
5342 women were sent letters describing the program and the
SOF-based risk factor questionnaire (Fig. 1). Of these, 2941
(55.1%) did not respond, 120 (2.2%) refused participation
and 20 (0.4%) could not be contacted. 2261 (42.3%) women
sent in a completed SOF-based risk assessment. 85 women
were determined to be ineligible due to osteoporosis medi-
cation use, resulting in a final sample size of 2176 partici-
pants in this group. Of these, 150 women (6.9%) reported 
5 risk factors and were invited by telephone to schedule a
bone density testing examination.
Components of the Intervention Program
The intervention program was identical for the 3 study
groups with the exception of how liberally bone density
testing was offered as described above. The program had 3
main components: (1) All women who completed a risk
factor questionnaire received personalized feedback identify-
ing their risk factors for osteoporosis and providing sugges-
tions for changing modifiable risk factors. (2) Accompanying
the personalized feedback was a professionally printed edu-
cational brochure developed by the investigators providing
information about osteoporosis and fracture and how it can be
prevented and treated. The information in this brochure was
consistent with prevention and treatment guidelines in place
at GHC. (3) Bone density testing examinations took place
from April 1998 through May 1999. Bone density was mea-
sured at the total hip and posterior–anterior spine by a trained,
certified technician with dual-energy x-ray absorptiometry
using a Hologic QDR 2000 densitometer (Hologic, Inc.,
Bedford, MA). Women who received bone density testing
received enhanced personalized feedback on their hip and
spine bone density. Their individual risk of hip fracture in the
next 10 years was estimated based on Rochester, Minnesota,
data and compared with the hip fracture risk of a woman with
average bone density of the same age. Pictorial images
showing the number of women in a thousand expected to
have a hip fracture at the 2 levels of bone density were used.
The criterion for referring women to their personal
physicians was identical for the 3 study groups. Consistent
with GHC Guidelines (based on the original SOF report),14
women with  5 fracture risk factors and low bone density
(T-score less than 2.5 for women 60–64 years or a z-score
less than 0.43 for women  65 years), along with all who
reported a prior fracture after the age of 50, were referred to
their personal physicians for work-up and treatment of pos-
sible osteoporosis. For these women, a copy of their person-
alized feedback was also sent to their personal physician.
Data Collection
Details of the baseline data collection have been de-
scribed in detail in a previous report.15 Briefly, all women
who participated in the bone density testing examination
completed a detailed baseline questionnaire assessing their
demographic characteristics, fracture risk factors (personal
history of fracture, dietary and supplemental calcium, phys-
ical activity, weight, height, use of selected medications), and
knowledge about osteoporosis and fracture prevention. For
women in the SCORE and SOF-based testing groups who
were not invited for bone density testing, the only informa-
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tion available at baseline was that provided on the respective
questionnaires.
Women who received bone density testing were ran-
domly allocated to receive a follow-up interview by tele-
phone at 6–18 months after their clinic examination to collect
information on the main trial outcomes. Interviews took place
from February 1999 through September 2000. Multiple at-
tempts were made to contact every screened woman. Tele-
phone interviews were completed with 399 women in the
universal group (96.1%), 391 women in the SCORE group
(92.0%), and 137 women in the SOF-based group (91.3%). A
paper-and-pencil follow-up questionnaire with a subset of the
interview items was mailed in May-July 2000 to women in
the SCORE and SOF-based testing groups who were not
offered bone density testing because of too few risk factors.
A second questionnaire mailing was used to maximize re-
sponse rates. Completed mailed questionnaires were received
from 91 of 151 women (60.3%) in the SCORE testing group
and from 1416 of 2026 women (69.9%) in the SOF-based
testing group. The responses from the telephone interview
and mailed questionnaires were merged within each group to
evaluate outcomes in the randomized groups.
Main Trial Outcomes
Several main trial outcomes were obtained for all
women via computerized GHC records. Initiation of osteo-
porosis therapy, including hormone replacement therapy,
alendronate, raloxifene, and calcitonin, was ascertained
through computerized GHC pharmacy records, indicating one
or more dispensed prescriptions for these agents during fol-
low-up through December 31, 2000. Hip and other fracture
events were regarded as exploratory outcomes and ascer-
tained through December 31, 2000, by searching automated
hospitalization and outpatient visit records for ICD-9 codes
indicating the occurrence of nonpathologic fracture. Fol-
low-up time for osteoporosis therapy initiation and fracture
occurrence ranged from 24–33 months with an average
duration of 28 months.
The follow-up telephone and mailed questionnaires
included items asking women if they had made any changes
to their diet or lifestyle in the last year because of concerns
about osteoporosis. A calcium intake scale was calculated by
summing the frequency of eating 4 types of dairy products
(milk, ice cream, yogurt, and cheese). An exercise scale was
calculated by summing the frequency of 3 types of usual
physical activity (taking walks, working around the house,
regular physical activity like brisk walking, jogging, bicy-
cling, etc.). Women were asked to rate their own risk of ever
getting a bone fracture compared with other women their age.
They were also asked to estimate how much of the time they
worry about taking a bad fall. Knowledge of osteoporosis risk
factors was ascertained by asking women which of 11 factors
increased a woman’s risk of developing osteoporosis.
Several elements of the intervention program were also
evaluated including: (1) the degree to which the women read
the educational brochure on osteoporosis; (2) the degree to
which they found the brochure useful; (3) whether the women
discussed osteoporosis with their primary care provider after
receiving their personalized feedback; (4) whether they
would like to see a fracture prevention program incorporated
into their usual care; and 5) how much they would like a bone
density testing program like this one to become part of their
routine preventive care (scale 1–10).
Statistical Analysis
Demographic characteristics and baseline levels of se-
lected fracture risk factors were compared among the 3
intervention groups using 2 tests. Rates of treatment initia-
tion and fractures were calculated as the number of events per
1000 women. Age-adjusted rates were calculated using the
direct method by using the age distribution of all trial partic-
ipants as the standard population. All women randomly
selected and allocated were included in these outcome anal-
yses. Rates are presented separately for all randomly selected
women who were invited to participate (an intention-to-
screen analysis) and for the subgroup who responded to the
invitation and became intervention program participants (par-
ticipant-only analysis). Note that all women were included in
these analyses regardless of whether they were offered BMD
testing or whether they provided follow-up data by interview
or mailed questionnaire.
Self-reported outcomes could only be evaluated among
women who participated in the intervention and provided
follow-up information. Contingency tables analyses com-
pared levels of these outcomes by intervention group. Statis-
tical tests comparing the 3 testing groups were calculated
using linear or logistic regression models with indicator
variables for intervention group and adjustment for age and
education. Inclusion of terms in the model indicating the time
of the follow-up interview produced identical results.
RESULTS
Baseline characteristics of women who agreed to par-
ticipate are shown in Table 1. The average age of the 3
intervention groups ranged from 69.1 to 70.3 years with the
SOF-based testing group having a higher frequency of
women aged 75 and older (Table 1). Most women had at least
some college education (62–69%). Most participants were
Caucasian (90–93%). History of fracture was highest in the
universal testing group (22.5%) and lowest in the SCORE
testing group (11.8%; P  0.0001). Approximately three
quarters of women reported walking for exercise.
Bone density testing was performed among 415 (100%)
women in the universal testing group, 425 (73.8%) women in
the SCORE testing group, and 150 (6.9%) women in the
SOF-based testing group (Fig. 1). Among the women who
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received bone density testing, 117 (28.2%) women in the
universal testing group, 136 (32.0%) women in the SCORE
testing group, and 89 (59.3%) women in the SOF-based
testing group met the GHC criteria for referral to their
personal physicians for work-up and possible treatment of
osteoporosis. An additional 305 (14%) women in the SOF-
based testing group who did not meet the BMD testing
criteria, but who reported prior history of fracture were
referred to their physicians for further evaluation.
Among all women randomly selected and contacted,
GHC computerized records yielded a total of 98 hip fractures
(25 in participants) and 747 total fractures (307 in partici-
pants) during follow-up. Among all women contacted, age-
adjusted rates of total fracture were lowest in the universal
testing group (74.11/1000), highest in the SCORE testing
group (99.44/1000; P  0.009) and intermediate in the
SOF-based testing group (91.77/1000; P  0.02). Hip frac-
ture rates were also lowest in the universal group (8.54/1000),
intermediate in the SCORE testing group (9.04/1000), and
highest in the SOF-based testing group (13.31/1000; Table 2)
but these differences were not statistically significant. Rates
of initiation of osteoporosis therapy did not differ signifi-
cantly among all women contacted but were slightly higher
among women who participated in the universal and SCORE
groups (21.1 and 20.2/100, respectively; P  0.76, compared
with 16.7/100 in the SOF-based group; P  0.04). Higher
rates of alendronate initiation appeared to account for most of
this difference (Table 2).
Self-reported outcomes are shown for all women who
participated in the intervention, including those who were not
offered BMD testing (Tables 3 and 4). Changes in diet or
lifestyle because of concerns about osteoporosis were re-
ported on the follow-up questionnaires more commonly
among women in the universal (49%) and SCORE testing
groups (44%) than in the SOF-based testing group (35%;
Table 3). The most commonly reported change was taking
calcium supplements, reported by one-third of women in the
universal testing group, 28% of women in the SCORE testing
group (P  0.65), and 27% of women in the SOF-based
testing group (P   0.0001). In contrast, women in the
SOF-based group more commonly reported increasing di-
etary calcium (P  0.0001 versus universal). Self-reported
TABLE 1. Baseline Characteristics of Trial Participants According to Intervention Group in the OPRA Trial
Screening Strategy
Universal,
n  415 (%)
SCORE,
n  576 (%)
SOF-Based,
n  2176 (%)
Age group†
60–64 24.8 25.2 20.1
65–69 29.6 25.9 24.4
70–74 26.0 27.1 26.9
75 19.5 21.9 28.6
Age, mean (SD) 69.1 (5.5) 69.3 (5.5) 70.3 (5.6)
Ethnicity
White 93.0 91.8 90.1
Black 1.5 2.0 2.4
Asian 3.6 4.0 4.6
Hispanic 1.5 1.2 1.4
Other 0.5 1.0 1.6
Total (n  415) (n  502) (n  1389)
Education*
High school or less 30.7 38.2 32.0
Some college 36.2 33.5 38.8
College grad or higher 33.1 28.3 29.2
Total (n  414) (n  508) (n  1508)
History of fracture since age 50† 22.5 11.8 17.3
History of rheumatoid arthritis 9.9 9.9
Current smoker 9.0 6.8
Walk for exercise 74.5 74.4
Analyses were restricted to women who participated in the trial including those who did and did not receive BMD testing.
*2 P  0.05.
†2 P  0.0001.
SD indicates standard deviation.
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data on osteoporosis therapy initiation was somewhat lower
than detected through the automated pharmacy data (Table 3)
caused, at least in part, by a shorter follow-up interval for the
self-report data. For self-reported hormone therapy and alen-
dronate, the highest initiation rates occurred in the universal
testing group and the lowest rates occurred in the SOF-based
group (Table 3). Women in the universal and SCORE testing
groups were much more likely to self-rate their risk of bone
fracture as “higher” or “much higher” than other women of
the same age as compared with women in the SOF-based
testing group (40–46% versus 8.3%, respectively; Table 3).
Intake of dairy products and exercise scale scores appeared
similar among the testing groups.
Knowledge about osteoporosis risk factors varied dra-
matically across the intervention groups (Table 3). Women in
the universal testing group reported the highest mean propor-
tion of correct answers (57%) as compared with women in the
SCORE testing group (53%; P  0.13) and women in the
SOF-based testing group (43%; P  0.0001). Across the
intervention groups, a third or fewer women knew that losing
a lot of weight or having a previous broken bone increased
risk of fracture.
About 77% of women in the universal testing group
reported having read all or some of the educational brochure
compared with 72% of women in the SCORE group and 44%
of women in the SOF-based group (Table 4). Women in the
universal testing group also were significantly more likely
to have discussed osteoporosis with their healthcare pro-
vider (45%) than women in the SOF-based testing group
(19.3%; P  0.0001); in contrast, about 38% of women in
the SCORE testing group had a discussion with their
healthcare provider (P  0.72 for SCORE versus universal
testing group).
Interest in seeing a fracture prevention program incor-
porated into routine clinical care was high, ranging from 82%
of women in the SOF-based testing group to 93% of women
in the universal testing group (Table 4). Levels of interest in
seeing a bone density program offered as part of routine care
were also high.
DISCUSSION
Many studies, both observational6–9 and experimen-
tal,10,11 have shown that bone density testing is associated
with higher rates of treatment initiation. In 8020 women
enrollees of a health maintenance organization in Northern
California, 24% of women undergoing bone density testing
filled a prescription for an osteoporosis drug within 6
months,7 a rate similar to the 21% of women initiating
treatment who participated in the universal group of the
OPRA Trial. Initiation of treatment appears to be associated
with having a bone density test regardless of the result,10 in
addition to test results indicating low bone density or osteo-
porosis.7–9 Ultimately, as many have noted,16,17 the outcome
of greatest importance is not treatment initiation but reduction
in fracture rates. Thus, the effects of bone density testing on
treatment adherence18 and long-term continuance deserve
further evaluation.
Previous studies have shown that women identified as
having low bone density are more likely to report increasing
their calcium intake, physical activity levels or making other
lifestyle changes compared with women without low bone
density.6,11,19–23 Few studies have been population-based or
randomly assigned women to different intervention groups.
Knowledge about osteoporosis was highest among
women in the universal group, even though all women re-
ceived the educational brochure and personalized risk factor
TABLE 2. Age-Adjusted Rates of Osteoporotic Fracture and
Initiation of Osteoporosis Treatment According to
Intervention Group in the OPRA Trial*
Screening Strategy Universal SCORE SOF-Based
All randomly selected women
invited to participate
1986 1940 5342
Intervention program
participants
415 576 2176
Osteoporotic fracture rate* per
1000
All randomly selected
women invited to participate
Hip 8.54 9.04 13.31
Any fracture 74.11 99.44† 91.77†
Intervention program
participants
Hip 3.22 7.95 8.74
Any fracture 89.26 116.34 92.76
% initiation of antiosteoporosis
therapy
All randomly selected
women invited to participate
Any type of therapy 12.60 13.78 13.33
HRT 9.62 10.61 10.59
Alendronate 2.67 2.81 2.11
Other 0.08 0.11 0.13
Intervention program
participants
Any type of therapy 21.14 20.22 16.73†
HRT 14.71 14.67 13.30
Alendronate 6.51 4.62 3.26
Other 1.89 2.44 1.60
*Fracture rates after initial contact. Mean follow-up (in months) was 27.0
(universal), 28.2 (SCORE), and 28.6 (SOF-based); range (23.5–33.2
months).
†P value compared with the universal group  0.05.
HRT indicates hormone replacement therapy.
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TABLE 3. Osteoporosis Risk Factors, Behaviors, and Knowledge of Fracture Risk Factors at Follow-Up According to
Intervention Group in the OPRA Trial
Universal
n  399
(%)
SCORE
n  482
(%)
SOF-based
n  1510
(%)
Made changes in diet or lifestyle in last year because of concerns about osteoporosis 48.9 43.6 35.3†
Changes made in last year
Ate more calcium 18.8 20.5 26.8†
Ate fewer fatty foods 12.0 15.2 25.5†
General diet improvement 11.5 15.2 23.4†
Take calcium supplements 33.1 28.4 27.3†
Exercise more often 24.6 24.9 23.4
Other 14.8 10.0 4.3†
Self-reported initiation of any of the following medications in last 12 months
Hormone replacement therapy 10.0 7.7 4.8*
Alendronate (Fosamax) 4.8 3.5 2.7
Calcitonin (Miacalin or Calcimar) 0.3 0.4 0.5
Raloxifene 0.0 0.6 0.5
Compared with other women of the same age, self-rated personal risk of bone fracture§
Lower 13.0 16.2 37.6†‡
Much lower 40.4 34.0 16.9
About the same 0.5 5.0 14.8
Higher 32.3 29.9 6.0
Much higher 8.0 6.6 2.3
Calcium intake scale
Never or rarely 7.3 5.8 7.4‡
Several times per month 44.9 44.4 49.5
Several times per week 45.6 47.9 38.9
Every day 2.0 1.5 2.5
Exercise scale* mean (standard deviation) 2.39 (0.54) 2.35 (0.58) 2.26 (0.66)
How much time do you worry about taking a bad fall?
All or most 8.5 11.6 9.8
A good bit or some 38.4 37.6 29.7
A little or none 52.6 49.6 56.3
Knowledge of osteoporosis risk factors
Menopause 76.9 71.4 51.9*
Family history of osteoporosis 85.5 82.1 67.3*
Smoking 75.4 68.1 53.3†
Being Caucasian 37.8 29.3 24.6*
Not getting enough calcium 97.2 95.6 82.0*
Not getting enough exercise 97.2 91.9 80.3*
Being overweight (“no” is correct) 13.5 12.0 11.9
Drinking caffeinated beverages 41.4 36.3 27.2*
Small build 40.4 34.2 25.4
Losing a lot of weight 29.8 28.8 16.6*
Previous broken bone 27.6 29.3 34.5†
Proportion of correct responses 0.57 0.53 0.43†‡
Analyses were restricted to women who participated in the trial including those who did and did not receive BMD testing.
*P  0.05 adjusted for age and education compared with universal.
†P  0.0001 adjusted for age and education compared with universal.
‡P  0.05 adjusted for age and education compared to SCORE.
§Percentages do not sum to 100% because of “don’t know” and “already have had fracture” responses.
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feedback. Less than one-third of women realized at follow-up
that losing a lot of weight or having a previous broken bone
increased risk of fracture. Reinforcement of intervening on
these important risk factors among both women and their
physicians is an important direction for improving fracture
prevention in populations.16
This trial was not designed to have sufficient num-
bers of women or duration of follow-up to provide defin-
itive data on risks of fracture associated with the various
testing strategies. Fracture rates were evaluated during a
2-year period and based on physician assigned ICD-9
codes, which were not further adjudicated. These limita-
tions argue for a cautious interpretation of the fracture
data. Nonetheless, in our exploratory analyses, total frac-
ture rates were significantly lower in the universal testing
group among all women contacted. The pattern was similar
for hip fracture, but the differences were not statistically
significant because few hip fractures occurred. Similarly,
hip fracture rates were lower in the Cardiovascular Health
Study among older adults offered bone density testing
compared with those receiving usual care (relative risk 
0.58 95% confidence interval 0.35– 0.97).24 It would be
highly desirable to subject bone density testing to evalua-
tion in large randomized trials with osteoporotic fractures
as the primary outcome of interest. The prospects of
conducting such a trial are daunting because testing and
consumer demand have grown dramatically during the past
10 years. In the interim, the fracture rates presented here
offer more evidence than has been available heretofore for
evaluating cost-benefit trade-offs as a basis for practice
guidelines in health care organizations.
Strengths of this trial include its population-base, rela-
tively large sample size, the ability to target the intervention at
older women not already receiving osteoporosis therapies, the
development and use of an innovative personalized feedback
system, and the use of automated data to ascertain treatment and
fracture outcomes among all women invited to participate. The
strategies tested did not require a physician recommendation for
screening and thus, do not generalize to interventions that rely on
physician referral. More than 1000 clinicians were practicing at
GHC when this trial was conducted, and no attempt was made
to evaluate physician variation in osteoporosis treatment. None-
theless, a widely promulgated osteoporosis guideline likely de-
creased practice variation and improved the quality of clinical
care in all intervention groups.
The fact that participation rates ranged from 21% to
42% across the intervention groups has important health
services implications. First, participation rates were higher
in the SCORE and SOF-based groups compared with the
universal group, suggesting that the requirement to return
a risk factor questionnaire at the initial contact did not
discourage participation. Many potentially eligible women
were not persuaded to participate by 2 letters of invitation
or the promise of bone density testing, suggesting that
TABLE 4. Participant Evaluation of the OPRA Fracture Prevention Program
Universal
n  399
SCORE
n  482
SOF-Based
n  1510
Read the informational brochure on osteoporosis
All 61.9 56.0 44.4†‡
Some 14.8 15.6 15.8
None 0.3 0.8 1.4
Never received or do not remember 3.8 8.3 20.3
How useful was the informational brochure?§
Very useful 22.1 23.4 26.0†‡
Somewhat useful 38.6 33.4 27.3
Slightly useful 7.5 8.1 4.0
Not at all 0.8 0.6 0.5
Had a discussion with healthcare provider during follow-up 44.9 37.8 19.3†
Interested in seeing a fracture prevention program incorporated
into care at GHC (range, 1–100)
93.0 89.2 81.9
Scale of interest in seeing a bone density program as part of
routine care offered at GHC (range, 1–100)
85.8 (20.8) 84.5 (22.0) 82.9 (24.6)
Analyses were restricted to women who participated in the trial including those who did and did not receive BMD testing.
*P  0.05 adjusted for age and education compared with universal.
†P  0.0001 adjusted for age and education compared with universal.
‡P  0.05 adjusted for age and education compared with SCORE.
§Percentages do not sum to 100% because of “don’t know” responses.
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health care systems will not be overwhelmed by high
response rates to offering fracture prevention services.
Differences between participants and nonparticipants are
beyond the scope of this paper and the subject of a separate
report.25 We necessarily elected to randomly allocate
women to the various testing strategies at the earliest
contact, so that participation rates could be evaluated in
response to a realistic packaging of the risk factor ques-
tionnaires and letters of invitation.
For the self-reported outcomes that required participa-
tion, we cannot rule out selection factors as an explanation of
some differences among the intervention groups. For exam-
ple, women in the universal group who self-selected to
participate reported making more behavioral changes because
of concerns about osteoporosis in the last year; calcium
supplementation was the most commonly reported change.
Thus, the universal invitation may result in selection of
women who are highly motivated to make changes based on
personalized feedback, whereas risk-based strategies would
exclude some of these women.
The findings presented here should also be evaluated in
the context of recent evidence from large pharmacologic trials.
First, randomized trials have shown that women without estab-
lished osteoporosis (vertebral fracture or low bone density) do
not significantly lower their risk of hip or clinical fracture by
treatment with bisphosphonates.26,27 Furthermore, the idea that
universal treatment of women with hormone therapy is war-
ranted because of its cardioprotective effects has been dis-
proven.28,29 These findings argue for targeting osteoporosis
therapies at the women most likely to benefit, specifically, those
with established osteoporosis as defined by vertebral fracture,
history of clinical fracture after age 50 and/or low bone densi-
ty.30 Moreover, women in this trial overwhelmingly indicated
their desire for fracture prevention programs that incorporate
bone density testing. These factors are compelling reasons for
incorporating bone density testing into well-designed programs
for osteoporosis detection and education in populations. Our
findings illustrate the fracture and risk reduction trade-offs for
directing services to women at greatest risk in health care
environments where BMD-testing resources are scarce.
We conclude that the degree to which bone density
testing was offered to women in a fracture prevention pro-
gram significantly affected total fracture rates, change in
some fracture risk factors and osteoporosis knowledge. This
evidence supports the recent U.S. Preventive Services
Taskforce recommendations that all women aged 65 and
older be screened routinely for osteoporosis.31
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APPENDIX
The SCORE Questionnaire (Appendix Fig. 1 ) and the SOF-Based
Questionnaire (Appendix Fig. 2) used in the present study.
APPENDIX FIGURE 1. SCORE Questionnaire.
APPENDIX FIGURE 2. SOF-Based Questionnaire.
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